{"id":241,"date":"2026-07-17T18:26:08","date_gmt":"2026-07-17T16:26:08","guid":{"rendered":"https:\/\/www.pqra.gr\/managed-entry-agreements-sharing-risk-in-greece\/"},"modified":"2026-07-17T18:29:43","modified_gmt":"2026-07-17T16:29:43","slug":"managed-entry-agreements-sharing-risk-in-greece","status":"publish","type":"post","link":"https:\/\/www.pqra.gr\/el\/managed-entry-agreements-sharing-risk-in-greece\/","title":{"rendered":"Managed Entry Agreements: Sharing Risk in Greece"},"content":{"rendered":"

When a payer cannot be certain a medicine is worth its price, the answer is increasingly not “no” — it is a contract that shares the uncertainty. Greece has just built its most ambitious version of that idea yet.<\/strong><\/p>\n

Managed entry agreements fall into two broad families. Financial-based<\/strong> arrangements — simple discounts, price-volume agreements, budget caps, dose capping — manage the money. Outcomes-based<\/strong> arrangements — coverage with evidence development, payment by results, conditional treatment continuation — tie payment to whether the medicine actually works in practice.<\/p>\n

The Greek legal basis<\/h2>\n

Negotiation in Greece runs through the Negotiation Committee, with the framework set out in Article 254 of Law 4512\/2018. Paragraph 9 — introduced in 2019 — sets out an explicit menu: discounts, volume-tiered discounts, outcomes-based agreements, indication-based agreements, risk-sharing agreements and milestone-based agreements. Negotiation is triggered where annual budget impact exceeds €3 million or annual per-patient cost exceeds €12,000.<\/p>\n

The Innovation Fund<\/h2>\n

The most significant recent development is Law 5302\/2026, which established a national Innovation Fund<\/strong> (\u03a4\u03b1\u03bc\u03b5\u03af\u03bf \u039a\u03b1\u03b9\u03bd\u03bf\u03c4\u03bf\u03bc\u03af\u03b1\u03c2). Several features deserve attention:<\/p>\n